



BioHarvest Sciences Inc.: Grant of Options and Investor Relations

Vancouver, BC / March 22, 2021 / BioHarvest Sciences Inc. (the “Company”, “BioHarvest”) (CSE: BHSC) announces that it has issued a total 5,223,800 incentive stock options. 880,000 incentive stock options were granted to consultants and 4,343,800 to the Company’s Chairman Zaki Rakib. The stock options granted are exercisable to purchase a common share of the Company at a price of \$0.51 per share for a term of 10 years.

750,000 stock options granted will vest quarterly over a 3-year period, 4,343,800 will vest quarterly over a 2-year period and 130,000 will vest monthly over a 10-month period.

Additionally, the Company informs the public that it extended its Investor Relations Agreement (the “Agreement”) with Justin Meikelm (the “Consultant”) to provide investor relations services to the Company. The Agreement has been extended for an additional 3 years, commencing January 1, 2021.

In consideration for his services, the Company is paying the Consultant a monthly fee of \$10,500. As per the Agreement, the consultant is eligible for a bonus of up to 3 months of his pay based on delivery of key aligned performance metrics. The agreement may be terminated by the Company on 75 days notice. As announced in the Company news release dated January 12, 2021, the Consultant was granted a total of 300,000 incentive stock options exercisable to purchase a common share of the Company at a price of \$0.36. The options are vesting quarterly over a 3-year period for a term of 10 years.

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director

Phone: 1 (604) 622-1186

Email: dave@bioharvest.com



Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.